ATE407209T1 - Cryptosporidium parvum antigene, deren antikörper und deren diagnostische und medische verbindungen - Google Patents

Cryptosporidium parvum antigene, deren antikörper und deren diagnostische und medische verbindungen

Info

Publication number
ATE407209T1
ATE407209T1 AT01944811T AT01944811T ATE407209T1 AT E407209 T1 ATE407209 T1 AT E407209T1 AT 01944811 T AT01944811 T AT 01944811T AT 01944811 T AT01944811 T AT 01944811T AT E407209 T1 ATE407209 T1 AT E407209T1
Authority
AT
Austria
Prior art keywords
antibodies
diagnostic
cryptosporidium parvum
medical compounds
parvum antigens
Prior art date
Application number
AT01944811T
Other languages
English (en)
Inventor
J Simonsen
Original Assignee
Univ Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manitoba filed Critical Univ Manitoba
Application granted granted Critical
Publication of ATE407209T1 publication Critical patent/ATE407209T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01944811T 2000-06-15 2001-06-15 Cryptosporidium parvum antigene, deren antikörper und deren diagnostische und medische verbindungen ATE407209T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21208300P 2000-06-15 2000-06-15

Publications (1)

Publication Number Publication Date
ATE407209T1 true ATE407209T1 (de) 2008-09-15

Family

ID=22789489

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06011952T ATE453714T1 (de) 2000-06-15 2001-06-15 Antigene aus cryptosporidium parvum, antikörper dagegen und diagnostische und therapeutische zusammensetzungen
AT01944811T ATE407209T1 (de) 2000-06-15 2001-06-15 Cryptosporidium parvum antigene, deren antikörper und deren diagnostische und medische verbindungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06011952T ATE453714T1 (de) 2000-06-15 2001-06-15 Antigene aus cryptosporidium parvum, antikörper dagegen und diagnostische und therapeutische zusammensetzungen

Country Status (8)

Country Link
US (4) US6808900B2 (de)
EP (2) EP1762620B1 (de)
AT (2) ATE453714T1 (de)
AU (1) AU6720601A (de)
CA (1) CA2411949C (de)
DE (2) DE60140972D1 (de)
ES (1) ES2313962T3 (de)
WO (1) WO2001096370A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
CA2635430A1 (en) * 2005-12-29 2007-08-23 Boehringer Ingelheim Vetmedica, Inc. Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs
DK2275132T3 (da) 2005-12-29 2021-05-17 Boehringer Ingelheim Animal Health Usa Inc Multivalente pcv2-immunogeniske sammensætninger og fremgangsmåder til at fremstille dem
WO2008064299A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
WO2008073464A2 (en) * 2006-12-11 2008-06-19 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
PT2094872T (pt) * 2006-12-15 2017-04-27 Boehringer Ingelheim Vetmedica Inc Tratamento de porcos seropositivos para o anticorpo anti-pcv2 com antigénio de pcv2
EP1941903A1 (de) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxe und Behandlung von PRDC
EP1958644A1 (de) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Vorbeugung und Behandlung von subklinischer PCVD
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
CN101932336B (zh) * 2007-12-31 2014-07-09 贝林格尔.英格海姆维特梅迪卡有限公司 有外来氨基酸插入的pcv2 orf2病毒样颗粒
KR20100113582A (ko) 2008-01-23 2010-10-21 베링거잉겔하임베트메디카인코퍼레이티드 Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
CN103503841B (zh) * 2013-09-29 2016-01-20 捷胜海洋装备股份有限公司 一种浮球牵引机的牵引结构
ES2778425T3 (es) 2013-10-02 2020-08-10 Boehringer Ingelheim Animal Health Usa Inc Variante de la proteína ORF2 del PCV2 y partículas similares a virus compuestas por esta

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024649A1 (en) * 1992-05-29 1993-12-09 The Regents Of The University Of California Cryptosporidium polypeptides, nucleic acid, vectors and methods of use
DE69329202T2 (de) * 1992-10-02 2001-03-29 Research Corp. Technologies, Inc. Methoden der erhöhung der sekretion von überexpremierten proteinen
US5591434A (en) 1993-05-26 1997-01-07 The United States Of America As Represented By The Secretary Of Agriculture DNA sequence encoding surface protein of cryptosporidium parvum
WO1998007320A1 (en) 1996-08-23 1998-02-26 North Carolina State University NEUTRALIZATION-SENSITIVE EPITOPES OF $i(CRYPTOSPORIDIUM PARVUM)

Also Published As

Publication number Publication date
EP1762620B1 (de) 2009-12-30
DE60135655D1 (de) 2008-10-16
US6808900B2 (en) 2004-10-26
EP1762620A3 (de) 2007-04-04
CA2411949C (en) 2012-05-22
US7850972B2 (en) 2010-12-14
WO2001096370A9 (en) 2002-09-19
US7288621B2 (en) 2007-10-30
US20120045464A1 (en) 2012-02-23
DE60140972D1 (de) 2010-02-11
CA2411949A1 (en) 2001-12-20
US8241871B2 (en) 2012-08-14
ES2313962T3 (es) 2009-03-16
US20020034516A1 (en) 2002-03-21
EP1294889A2 (de) 2003-03-26
ATE453714T1 (de) 2010-01-15
US20050064553A1 (en) 2005-03-24
EP1294889B1 (de) 2008-09-03
AU6720601A (en) 2001-12-24
WO2001096370A3 (en) 2003-01-03
US20080299143A1 (en) 2008-12-04
WO2001096370A2 (en) 2001-12-20
EP1762620A2 (de) 2007-03-14

Similar Documents

Publication Publication Date Title
DE60135655D1 (de) Cryptosporidium parvum antigene, deren antikörper und deren diagnostische und medische verbindungen
CY1122505T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
DE69637642D1 (de) Und kombinierte zusammensetzungen und deren verwendung
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1108387T1 (el) Ανταγωνιστες ανασυνδυασμενης il-18 χρησιμοι στη θεραπεια παθησεων που εμφανιζονται με διαμεσολαβηση της il-18
DE60027890D1 (de) Streptococcus pneumoniae proteine und impfstoffe
AU9063801A (en) Methods and compositions for diseases associated with amyloidosis
DE60237778D1 (de) Antikörper gegen kdr, deren herstellung und verwendungen
ATE196314T1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
TR200200633T2 (tr) Yeni streptococcus antijenleri
PL365951A1 (pl) Związki oraz sposoby leczenia i diagnozowania infekcji Chlamydia
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
ATE517920T1 (de) Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
IL141775A0 (en) Aglyco products and methods of use
MXPA04006517A (es) Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
WO2005007673A3 (en) Immunogenic peptides
CY1114577T1 (el) Αποτροπη και θεραπεια υπο-κλινικης pcvd
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
WO2002024739A3 (en) Spas-1 cancer antigen
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
DE60335610D1 (de) Neoplasma-spezifische antikörper und deren verwendungen
ATE313560T1 (de) Therapeutische anti-cytomegalovirus verbindungen
DK1523985T3 (da) Ikke-radioaktivt strontiumholdigt middel til behandling af kræft
DE60024977D1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties